AAPS Science360

The year 2024 marked a significant milestone for TIL therapies with the FDA's approval of lifileucel (AMTAGVI), making it the first TIL-based treatment available for patients with solid tumors who have not responded to previous chemotherapy or immune checkpoint inhibitors [1]. Lifileucel, was shown in clinical trials to reduce tumor size in nearly one-third of participants, with some achieving complete tumor regression. Additionally, about 40% of responders had no cancer progression a year after receiving the one-time infusion, demonstrating the potential of TIL therapy in advanced melanoma treatment [2]. This article discusses the definition, current progression, potential future applications, and challenges faced in the development of TIL therapy based on scientific findings. 

Melanoma is a malignant neoplasm of the skin, arising from melanocytes and is often associated with increased ultraviolet (UV) radiation exposure [3]. Based on recent data, melanoma of the skin accounts for approximately 5% of all new cancer cases in the U.S., with an estimated 104,960 new cases expected in 2025. Despite being one of the most common cancer types, its 5-year relative survival rate is remarkably high at 94.7%, largely due to improvements in early detection and treatment options [4]. Though, the management of metastatic melanoma has posed many challenges for oncologists, historically relying on surgery, radiation therapy, and chemotherapy, which have often proved to be inadequate in the advanced disease stages. The conventional treatment options face limitations. 

Melanoma often develops resistance to traditional treatments, leading to disease recurrence and progression. This resistance is due to the tumor's ability to pass the immune system undetected, most likely by creating an immunosuppressive microenvironment that includes regulatory T cells and myeloid-derived suppressor cells [3][5]. Additionally, advanced melanoma frequently metastasizes to distant organs, complicating treatment and resulting in poor prognostic outcomes [6]. Immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1, as well as BRAF and MEK inhibitors, have significantly improved melanoma treatment. Some challenges remain, especially concerning addressing brain metastases, some rare melanoma subtypes such as uveal and mucosal melanoma, as well as resistance to existing therapies.[7]. Furthermore, the tumor microenvironment (TME) of melanoma uses several approaches to escape immune detection, including the overexpression of immune checkpoints such as PD-1 and CTLA-4, which suppress T cell activation and activity. This factor alone is enough to greatly reduce the effectiveness of immunotherapeutic approaches [8]. 

As conventional therapies face limitations in addressing these challenges, approaches like TILs therapy (a form of adoptive cell transfer (ACT)) offer a promising avenue by using the body's own immune cells to treat melanoma. Tumor-infiltrating lymphocytes (TILs) are immune cells naturally found within tumors, where they exhibit the ability to recognize and attack cancer cells [1]. These lymphocytes are selectively harvested from the tumor tissue, focusing on those with the highest tumor-killing potential. Once isolated, the TILs are expanded ex-vivo in the laboratory using growth factors like IL-2 to amplify their numbers and effectiveness [7]. The advanced TILs are then reintroduced into the patient, enabling the immune system to better recognize and eliminate the metastatic melanoma cells. 

Recent studies have reported response rates for TIL therapy in heavily pretreated melanoma patients ranging from 30% to 50%, with responses lasting many months or years. This suggests that TIL therapy can provide a new lifeline for patients who are resistant to other forms of treatment [9][10].

Figure 1: Tumor-Infiltrating Lymphocyte (TIL) therapy process, where immune cells from a patient’s tumor are expanded in the lab and reinfused with IL-2 after chemotherapy to fight cancer. [2] 

Recent developments have concentrated on identifying and purifying tumor-specific TILs, especially those capable of rapid multiplication. Studies have identified markers such as PD-1, Tim3, and CD39 that can help isolate more effective TILs for therapy [8]. These optimizations are aimed at improving both the efficacy and persistence of TIL therapy in vivo. 

Lifileucel has demonstrated significant progression-free survival (PFS) and overall survival (OS) rates when compared to traditional therapies. For instance, lifileucel regimen has shown a median OS of approximately 17.4 months for patients who were treatment-refractory and has been associated with durable responses, indicating a promising therapeutic landscape for TILs in managing advanced melanoma [9]. 

Given the encouraging results with lifileucel, the future of TIL therapy holds substantial potential, particularly when combined with other treatment modalities. Building on these scientific findings, combination therapies are being explored to further enhance the efficacy of TIL therapy. Integrating TILs with immune checkpoint inhibitors or targeted therapies could not only improve treatment outcomes but also offer the possibility of complete melanoma eradication. 

The outlook for Tumor-Infiltrating Lymphocyte (TIL) therapy is very promising, with ongoing research exploring multiple avenues for expansion beyond metastatic melanoma. As TIL therapy evolves, it is crucial to consider how it can be combined with existing FDA-approved immunotherapy strategies for melanoma [11].  

Immune checkpoint inhibitors have revolutionized melanoma treatment by blocking inhibitory pathways that suppress T cell activation. Specifically, CTLA-4 inhibitors (e.g., ipilimumab) and PD-1 inhibitors (e.g., nivolumab and pembrolizumab) release the “brakes” on T cells, allowing them to mount a more robust anti-tumor response [12]. Combining TIL therapy with these checkpoint inhibitors could enhance TIL functionality. For instance, PD-1 blockade may rejuvenate exhausted TILs, restoring their cytotoxic activity against melanoma cells [13]. Moreover, dual checkpoint inhibition (e.g., nivolumab with ipilimumab) could increase the effectiveness of TIL activity by targeting complementary pathways. By utilizing immune checkpoint blockade, TIL therapy could potentially overcome immunosuppressive mechanisms within the tumor microenvironment, leading to more anti-cancer effects. 

Cytokines play a crucial role in supporting TIL expansion. Interleukin-2 (IL-2) is widely used in TIL therapy to promote the proliferation and activation of T cells. High-dose IL-2 administration increases the cytotoxic potential of TILs; however, it is often accompanied by significant toxicity [14][15]. Emerging strategies aim to optimize cytokine regimens by including use of alternative cytokines, such as IL-15 and IL-21, which promote TIL proliferation with reduced toxicity. Additionally, genetically modifying TILs to express cytokines like IL-12 can boost their persistence and anti-tumor activity. Combining TIL therapy with cytokine modulators could significantly amplify the immune response against melanoma cells while minimizing adverse effects [16]. 

Oncolytic viruses (e.g., talimogene laherparepvec, or T-VEC) selectively infect and lyse tumor cells, releasing tumor-associated antigens (TAAs) and promoting an inflammatory microenvironment [16]. This boosts antigen presentation and allows for TIL infiltration into the tumor site. Combining TIL therapy with oncolytic virus treatment could synergistically enhance anti-tumor immunity. The oncolytic virus-induced inflammation recruits TILs to the tumor microenvironment, while TILs provide targeted cytotoxic activity against melanoma cells [17]. Additionally, genetically engineered oncolytic viruses expressing cytokines such as GM-CSF could further stimulate the immune response, creating a potent anti-tumor environment [16]. 

Cancer vaccines work by presenting specific tumor-associated antigens TAAs to the immune system, thereby generating a targeted T cell response. In melanoma, vaccines like the bacillus Calmette-Guérin (BCG) vaccine and peptide-based vaccines have demonstrated potential in activating anti-tumor immunity [18]. Vaccination with neoantigens identified through genomic sequencing may improve TIL specificity and potency against melanoma cells [19]. Additionally, personalized cancer vaccines tailored to the patient’s unique mutational profile could maximize TIL reactivity and reduce off-target effects, paving the way for more precise immunotherapies. 

However, here are many challenges that may be present when dealing with these therapies: 

These challenges highlight the critical need for continued research and development to overcome these limitations and improve the effectiveness and success of these groundbreaking therapies. 

In conclusion, TIL therapy stands as a promising and innovative approach in cancer immunotherapy, highlighted by the FDA approval of lifileucel for metastatic melanoma in 2024. Its potential to enhance anti-tumor immunity and provide durable responses marks a significant advancement in personalized cancer treatment. However, despite its promise, several challenges remain, including the complexity of TIL manufacturing, variability in patient response, and the need to overcome immunosuppressive tumor microenvironments. Addressing these limitations through continued research and optimizing integration with existing immunotherapies will be crucial. 

As our understanding of TIL production and tumor biology continues to evolve, there is substantial potential to expand its application to a broader range of cancers. Future investigations into personalized treatment approaches, optimized TIL production, and combination strategies will be essential for maximizing therapeutic impact. Additionally, improving the flow and cohesiveness of ongoing research will help refine these techniques and facilitate their integration into existing oncological frameworks. 

While TIL therapy represents a significant leap forward, maintaining an unbiased perspective is essential. A comprehensive evaluation of both its potential and limitations will provide a more accurate outlook on its role in the future of cancer treatment. Ongoing research and transparent reporting will pave the way for more effective, personalized immunotherapy strategies.